Press Releases

Date Title and Summary Additional Formats
Toggle Summary Pivotal Phase III trial of abaloparatide-SC in Japanese women and men with osteoporosis achieves primary endpoint
Radius partner Teijin Pharma has submitted a New Drug Application  for abaloparatide-SC for treatment of osteoporosis in Japan   WALTHAM, Mass. , May 27, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS), today announced that its partner, Teijin Pharma Limited
View HTML
Toggle Summary Radius Health Announces First Quarter 2020 Operating Results
TYMLOS® U.S. net sales of $48 million, with 61% year over year growth Our three Phase 3 studies continue to advance amid slowdown in recruitment due to COVID-19 pandemic. Anticipated data read-outs remain on track for second half of 2021 Due to anticipated impact of pandemic, 2020 TYMLOS U.S.
View HTML
Toggle Summary Radius Health Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. , April 28, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq:RDUS) today announced that the Company’s Board of Directors (the “Board”) granted G. Kelly Martin , in connection with his appointment as Chief Executive Officer and President of the Company,
View HTML
Toggle Summary Radius Health Announces CEO Leadership Transition
Jesper Hoeiland to step down as President and Chief Executive Officer in order to return to Denmark with his family Jesper will serve as a Senior Advisor to the Company to help facilitate a smooth transition Kelly Martin has been appointed President and Chief Executive Officer WALTHAM, Mass.
View HTML
Toggle Summary Radius Health to Announce First Quarter 2020 Financial Results, Host Conference Call and Live Webcast on Thursday May 7, 2020
WALTHAM, Mass. , April 20, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its first quarter financial results on Thursday, May 7, 2020 . The Company will host a conference call and live audio webcast at 4:45 p.m.
View HTML
Toggle Summary Radius Health to Present at Cowen 40th Annual Healthcare Conference
WALTHAM, Mass. , March 03, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland , President & CEO and Pepe Carmona , CFO will present a corporate update at the Cowen 40 th Annual Healthcare Conference in Boston at 08:40 a.m.
View HTML
Toggle Summary Radius Health Announces Fourth Quarter and Full-Year 2019 Operating Results
TYMLOS ® U.S. net sales grew to $56 million in the fourth quarter of 2019,  totaling $173M for full-year 2019, exceeding the Company’s guidance of $168 to 172M TYMLOS exited 2019 with majority share in new patients 1 , on track for market leadership in 2020 2020 TYMLOS U.S.
View HTML
Toggle Summary Radius Health to Present at 9th Annual SVB Leerink Partners Global Healthcare Conference
WALTHAM, Mass. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS), today announced that Jesper Høiland, President & CEO and Pepe Carmona , CFO will present a corporate update at the 9 th Annual SVB Leerink Partners Global Healthcare Conference at 10:30 a.m.
View HTML
Toggle Summary Radius Health to Announce Fourth Quarter and Full Year 2019 Financial Results, Host Conference Call and Live Webcast on Thursday, February 27, 2020
WALTHAM, Mass. , Feb. 13, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2019 financial results on Thursday, February 27, 2020 . The Company will host a conference call and live audio webcast at 8:00 a.m.
View HTML
Toggle Summary Radius Exceeds 2019 Financial Guidance and Provides Business Update at the 38th Annual J.P. Morgan Healthcare Conference
Full-Year 2019 TYMLOS U.S. net revenue exceeds financial guidance, surpassing $172M . TYMLOS exits 2019 with 52% market share in new patients 1 , on track for market leadership in 2020. Radius delivers strong year-end balance sheet with $160M cash 2 balance and expects to achieve profitability
View HTML